Obicetrapib (1) – Ubeslo®
Primary hypercholesterolaemia or mixed dyslipidaemia
Characteristics
| Start date | 15.11.2026 |
|---|---|
| Resolution | 05.05.2027 – active procedure |
| INN | Obicetrapib |
| Brand name | Ubeslo® |
| Pharm. company | Berlin-Chemie AG/Menarini Group |
| G-BA Procedure ID | D-1392 |
| Therapeutic area | Metabolic diseases |
| Reason for procedure | Initial assessment |
Associated procedures
<< List of all resolutions